drugset / Trial / NCT00095108
Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is being done to see if an experimental drug called recombinant interleukin-21 (rIL-21) when given to patients with stage 4 malignant melanoma or stage 4 kidney cancer is safe and has any effect on these types of cancers.
Timeline
- Start
- 2004-05
- Primary completion
- 2007-01
- Completion
- 2007-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant Human Interleukin-21 | Protein / enzyme biologic | — | — |